Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?

Bispecific antibodies (bsAbs) have emerged as powerful therapeutic tools, especially in oncology and immunotherapy. By engaging two different antigens simultaneously, they offer functional versatility beyond monoclonal antibodies, whether by redirecting immune cells, blocking dual signalling pathways, or enhancing tumor selectivity. With numerous bsAbs now in clinical trials and a few already approved, the race is on to accelerate their development ¹.

Speed has become a strategic advantage. Stakeholders from biotech founders to global pharma feel increasing pressure to fast-track bispecific antibody projects ². Advances in transient expression systems, purification techniques, and protein engineering have made speed more achievable than ever. 

However, fast-tracking is not without risk. Compressed timelines can amplify the consequences of suboptimal design, reduce analytical scrutiny, and jeopardize long-term scalability. In this article our expert in bispecific antibody production services explore the hidden pitfalls of rapid bsAb development and outlines best practices for balancing speed with rigor and quality from the outset.

The appeal of fast-tracking bsAb development

Speed is a competitive necessity in today’s biopharma landscape. Rapid entry into clinical trials boosts investor confidence, enhances company valuation, and increases the likelihood of market exclusivity ³. This is particularly relevant for bsAbs targeting well-characterized cancer antigens or immune checkpoints, where several contenders may be racing toward the same clinical niche ⁴.

Technological advances have helped enable this acceleration. Transient CHO expression systems, improved cloning and sequencing platforms, and rational design software allow companies to go from DNA to functional protein within weeks. Novel Fc engineering and pairing strategies, such as bYlok®, further support rapid assembly of bispecific constructs with high fidelity ⁵.

However, speed should not compromise foundational quality standards. The drive for fast timelines must be weighed against the downstream implications of cutting corners.

Common challenges in fast-tracked bsAb development

Accelerating speed in bsAb development doesn’t come without challenges. These are the most common hurdles to overcome for pharmaceutical companies.

Format selection pitfalls

Selecting the right bsAb format is critical and bears numerous complexities. Formats vary in terms of geometry, valency, Fc inclusion, and linker design, each influencing manufacturability, pharmacokinetics, and mode of action ⁶. 

Under time pressure, teams may default to formats they’ve used before, even if suboptimal for the biology at hand. The wrong format can impair target engagement or Fc function, hinder large-scale expression, or trigger immunogenicity ⁷. Poorly chosen geometries may also result in rapid clearance or off-target binding, undermining therapeutic viability.

Expression and production hurdles

Time constraints often limit the optimization cycles needed to troubleshoot low expression yields or chain mispairing issues. Many bsAb constructs exhibit asymmetric heavy/light chain pairing, increasing the risk of product heterogeneity ⁸. Without sufficient time for construct refinement, developers may face low yields, poor reproducibility, or proteins unsuitable for downstream assays ⁹.

These early compromises, while expedient in the short term, resurface in many cases later as manufacturing inefficiencies or inconsistent preclinical data.

Purification and quality bottlenecks

Bispecific constructs, especially those lacking Fc regions or incorporating tandem scFv domains, can pose significant downstream purification challenges. Standard protein A affinity methods may not suffice, necessitating complex orthogonal purification steps ¹⁰. This adds time, cost, and regulatory complexity.

Rushing this phase increases the risk of retaining product-related impurities, such as homodimers, aggregates, or mispaired chains. These impurities can distort functional readouts or raise immunogenicity concerns which present producers with issues that are difficult to resolve later in development.

Functional characterization risks

Thorough in vitro and in vivo characterization is essential to identify binding specificity, signalling outcomes, and potential toxicity. Unfortunately, compressed timelines often result in minimal assay panels, missing critical liabilities like cytokine storm potential in T-cell engagers ¹¹ or unexpected cross-reactivity ¹².

Incomplete functional profiling is especially dangerous in bsAbs, whose dual-target nature introduces complex pharmacodynamics and safety considerations that monovalent formats do not pose.

Regulatory and scalability implications

Fast-tracked bsAbs may rely on proprietary or unvalidated expression systems that prove challenging to scale or transfer under GMP conditions. Similarly, rushed designs may lock developers into formats with unclear regulatory paths or IP constraints. These issues surface only during IND preparation or commercial partnering ¹³.

Neglecting these future-facing considerations can stall or derail programs just when they’re gaining momentum ¹⁴.

Strategic recommendations for fast, yet robust bsAb development

To accelerate without compromising quality, developers should adopt a parallelized, risk-aware approach:

Integrate design, engineering, and analytics early

Format selection should be driven by both biological rationale and manufacturability insights. Early developability assessments—covering solubility, aggregation risk, and expression yields—de-risk candidates from the start ¹⁵.

Prioritise high-fidelity expression platforms

CHO-based systems with robust pairing technologies, such as bYlok® or knobs-into-holes, reduce misassembly and ensure reproducible yields at both research and preclinical scales.

Parallelize workflows

Run expression, purification, and functional assays in synchrony to reduce total development time without skipping critical steps ¹⁶.

Choose experienced CDMO partners

Specialized CDMOs bring both infrastructure and scientific expertise to bear, enabling rapid, high-quality production that aligns with later-stage needs. Their knowledge can also help avoid regulatory missteps and scale-up inefficiencies.

Apply Quality by Design (QbD) principles early

Embedding quality considerations in design and testing enables smoother transitions to IND and commercial stages. Even when timelines are short, data integrity and process consistency should never be compromised.

How evitria supports accelerated and safe bsAb development

At evitria, we believe that speed and safety must go hand in hand. That’s why our bispecific antibody services are built to deliver both: Fast timelines without compromising reproducibility or manufacturability.

Our bYlok® pairing technology enables correct heavy/light chain assembly in >95% of cases, significantly reducing mispairing risks. Combined with our CHO-based transient expression platform, we offer high-yield, scalable production that supports candidate screening and clinical translation.

Our scientific team works closely with you on format selection, Fc engineering, and developability planning, ensuring that your bsAb candidates are not only produced quickly, but produced right. Whether you’re in early discovery or preparing for IND-enabling studies, we help accelerate your development path without unnecessary risk. We are the experts in recombinant antibody production services

References:

1. Labrijn, Aran F et al. “Bispecific antibodies: a mechanistic review of the pipeline.” Nature reviews. Drug discovery vol. 18,8 (2019): 585-608. doi:10.1038/s41573-019-0028-1 ↩︎
2. Klein, Christian et al. “The present and future of bispecific antibodies for cancer therapy.” Nature reviews. Drug discovery vol. 23,4 (2024): 301-319. doi:10.1038/s41573-024-00896-6 ↩︎
3. Mercedes Herrera, Giulia Pretelli, Jayesh Desai, Elena Garralda, Lillian L. Siu, Thiago M. Steiner, Lewis Au, “Bispecific antibodies: advancing precision oncology”. Trends in Cancer. Volume 10, Issue 10, 2024. https://doi.org/10.1016/j.trecan.2024.07.002 ↩︎
4. Mirasol, Feliza. “The Benefit of Technological Advancements to BsAb Development”. BioPharm International. 2024. URL: https://www.biopharminternational.com/view/benefit-technological-advancements-bsab-development. Accessed July 8, 2025. ↩︎
5. Madsen, Andreas V et al. “Design and engineering of bispecific antibodies: insights and practical considerations.” Frontiers in bioengineering and biotechnology vol. 12 1352014. 25 Jan. 2024, doi:10.3389/fbioe.2024.1352014 ↩︎
6. Brinkmann, Ulrich, and Roland E Kontermann. “The making of bispecific antibodies.” mAbs vol. 9,2 (2017): 182-212. doi:10.1080/19420862.2016.1268307 ↩︎
7. Wang, Qiong et al. “Design and Production of Bispecific Antibodies.” Antibodies (Basel, Switzerland) vol. 8,3 43. 2 Aug. 2019, doi:10.3390/antib8030043 ↩︎
8. Li, H., Er Saw, P. & Song, E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 17, 451–461 (2020). https://doi.org/10.1038/s41423-020-0417-8 ↩︎
9. Chen, Serene W, and Wei Zhang. “Current trends and challenges in the downstream purification of bispecific antibodies.” Antibody therapeutics vol. 4,2 73-88. 7 May. 2021, doi:10.1093/abt/tbab007 ↩︎
10. Haber, Lauric et al. “Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.” Scientific reports vol. 11,1 14397. 13 Jul. 2021, doi:10.1038/s41598-021-93842-0 ↩︎
11. Lin, Shihua et al. “Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA.” Frontiers in immunology vol. 16 1612547. 18 Jun. 2025, doi:10.3389/fimmu.2025.1612547 ↩︎
12. Yao, Xia et al. “Large scale controlled Fab exchange GMP process to prepare bispecific antibodies.” Frontiers in bioengineering and biotechnology vol. 11 1298890. 12 Jan. 2024, doi:10.3389/fbioe.2023.1298890 ↩︎
13. Amash, Alaa et al. “Developability considerations for bispecific and multispecific antibodies.” mAbs vol. 16,1 (2024): 2394229. doi:10.1080/19420862.2024.2394229 ↩︎
14. Alice Harrison, Stuart Jamison. “Rapid method to overcome challenges of bi-specific antibody purification.” European Pharmaceutical Review, 27 Apr. 2022, https://www.europeanpharmaceuticalreview.com/article/172584/rapid-method-to-overcome-challenges-of-bi-specific-antibody-purification/. Accessed July 8, 2025. ↩︎
15. evitria. “Bispecific Antibodies.” URL:  https://www.evitria.com/bispecific-antibodies. Accessed July 10, 2025. ↩︎
16. evitria. “Therapeutics Development.” URL: https://www.evitria.com/therapeutics-development. Accessed July 10, 2025. ↩︎